In a related therapeutic study in patients with metastatic salivary gland cancer doses of 177Lu-617 PSMA in salivary gland tumors were noted as moderate to weak, even though administered doses were the same as given to PC patients (6). This evidence concerns the gene FOLH1 and tumor of salivary gland.